Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

What You'll Want to Know About Pfizer's Q2 Earnings Results

By Keith Speights - Jul 29, 2019 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No big surprises with Pfizer's Q2 earnings results. The big surprise was a major deal with Mylan that caused the results to be announced earlier than expected.

Pfizer ( PFE 2.32% ) was scheduled to report its second-quarter earnings results on Tuesday, July 30. But that was before the big drugmaker announced that it's merging its Upjohn unit with Mylan. As a result of this big news, Pfizer released its Q2 results before the market opened on Monday, a day earlier than expected.

It's probably appropriate that Pfizer mixed things up with its earnings announcement schedule. Its Q2 earnings results were mixed, too. Here's what you need to know from Pfizer's latest quarterly update.

Multi-colored pills forming a dollar sign

Image source: Getty Images.

By the numbers

Pfizer reported Q2 revenue of $13.3 billion, down 2% year over year. The company's revenue also came in lower than the consensus Wall Street estimate of $13.4 billion.

There was better news from Pfizer about its bottom line, though. The drugmaker announced net income on a generally accepted accounting principles (GAAP) basis of $5.05 billion, or $0.89 per share. This GAAP earnings per share reflected a 37% jump over the prior-year period.

The company posted non-GAAP adjusted earnings in the second quarter of $4.52 billion, down 2% year over year. However, Pfizer's adjusted earnings per share in Q2 came in at $0.80, a 4% increase over the prior-year period. It also topped the average analysts' estimate of $0.75. 

Behind the numbers

I had expected currency headwinds for Pfizer in Q2. Sure enough, foreign exchange fluctuations turned out to be problematic for the company. On a constant-currency basis, Pfizer's total revenue would have increased by 2% year over year instead of dropping 2%.

It's no surprise that Pfizer's biopharma segment was its best-performing business in the second quarter, with year-over-year revenue climbing 2% to $9.6 billion. Ibrance and Eliquis generated operational sales growth of 27% and 26%, respectively. Xeljanz was the biggest winner among Pfizer's top drugs, with sales soaring 36% year over year on an operational basis.

However, sales slipped 10% year over year for Pfizer's top-selling product, pneumococcal vaccine Prevnar 13. The company said that this decline was primarily due to lower government purchases in the second quarter and slipping sales in the adult market.

Revenue for the Upjohn segment fell 11% from the prior-year period to $2.8 billion. This unit experienced a 20% operational sales decline in China mainly as a result of the March 2019 implementation of a volume-based purchasing program in some Chinese cities. Sales for Viagra continued to fall due to increased generic competition. Also, Pfizer reported that sales for Lyrica dropped with wholesalers destocking ahead of generic versions of the drug hitting the market.

Pfizer's consumer healthcare segment posted Q2 revenue of $862 million, down 3% year over year. Sales increased 1% operationally, though, with 4% operational growth in international markets offset partially by a 2% drop in U.S. revenue.

Looking ahead

Pfizer now expects full-year 2019 revenue between $50.5 billion and $52.5 billion. That's lower than its guidance, provided in April, of full-year revenue between $52 billion and $54 billion. This downward revision is due to the anticipated formation of the consumer healthcare joint venture with GlaxoSmithKline in August and the expected close of Pfizer's acquisition of Array BioPharma.

The drugmaker also now looks for adjusted earnings per share for full-year 2019 between $2.76 and $2.86. Pfizer previously projected full-year adjusted EPS of $2.83 to $2.93.

Of course, the really big development to look forward to is Pfizer's planned merger of its Upjohn unit with Mylan. Pfizer CEO Albert Bourla stated that he expects completing this transaction will put Pfizer in a position "to deliver revenue and adjusted diluted EPS growth through the mid-2020s that is among the industry leaders." He also added that Pfizer would continue to "allocate significant capital directly to shareholders, primarily through dividends." 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.27 (2.32%) $1.23
Viatris Inc. Stock Quote
Viatris Inc.
MYL
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$41.25 (-0.53%) $0.22
Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
ARRY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.